| abstract |
The invention relates to compounds of the general formula (I)n and physiologically acceptable salts and solvates thereof; nwherein: nR¹ and R² each independently represent a hydrogen atom or a C₁₋₃alkyl group with the proviso that the sum total of carbon atoms in R¹ and R² is not more than 4; nX represents a direct bond or a C₁₋₇alkylene, C₂₋₇alkenylene or C₂₋₇alkynylene group and Y represents a direct bond or a C₁₋₆alkylene, C₂₋₆alkenylene or C₂₋₆alkynylene group with the proviso that the sum total of carbon atoms in X and Y is not more than 10; nW represents a groupn wherein Z represents a group R³(CH₂) q where q is 0, 1 or 2 and R³ is a group R⁴CONH-, R⁴NHCONH-, R⁴R⁵NSO₂NH-, R⁶SO₂NH- or -OH; nR⁴ and R⁵ each represent a hydrogen atom or a C₁₋₃alkyl group; nR₆ represents a C₁₋₃alkyl group; nR⁷ represents a chlorine atom or the group -CF₃; nA represents a straight or branched C₁₋₆alkyl group, a C₃₋₈cycloalkyl group, either of which may be saturated or unsaturated, or a C₁₋₆alkoxy group, with the proviso that the sum total of carbon atoms in A and Y is not less than 5. n The invention also relates to processes for making the compounds of formula (I) and to pharmaceutical compositions containing them as active ingredient. n The compounds of formula (I) have a stimulant action at β₂-adrenoreceptors and are useful in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis. |